Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Current treatments for unresectable or metastatic BRAF V600 mutation-positive melanoma include targeted therapy, usually using a combination of a BRAF and MEK inhibitor (dabrafenib with trametinib) or sometimes monotherapy with a BRAF inhibitor (vemurafenib or dabrafenib). Clinical trial evidence shows that, compared with vemurafenib, encorafenib with binimetinib extends the time until melanoma progresses and also how long people live. There are no trials directly comparing it against ...

NICE

National Institute for Health and Clinical Excellence (NICE)

There are currently no adjuvant immunotherapies recommended by NICE for routine use in people who have melanoma with lymph node involvement or metastatic disease, who have had complete resection. Clinical evidence from CheckMate 238, an ongoing randomised trial, shows that nivolumab improves recurrence-free survival compared with ipilimumab. There are currently no trials comparing nivolumab with routine surveillance, which is the standard of care in the NHS. An indirect treatment comparison ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Standard care in people with untreated, metastatic non-squamous NSCLC whose tumours have no EGFR- or ALK‑positive mutations is usually pemetrexed with carboplatin or cisplatin. For people who cannot tolerate this, docetaxel, gemcitabine, paclitaxel or vinorelbine with carboplatin or cisplatin can be offered. People on either of these combinations may also have pemetrexed maintenance therapy. Standard care for people whose tumours express at least a 50% tumour proportion score is usually ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Offer an antibiotic(s) for adults, young people and children with hospital-acquired pneumonia. Start antibiotic treatment as soon as possible after establishing a diagnosis of hospital-acquired pneumonia, and certainly within 4 hours (within 1 hour if the person has suspected sepsis and meets any of the high risk criteria for this. Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics. If intravenous ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Start antibiotic treatment as soon as possible after establishing a diagnosis of community-acquired pneumonia, and certainly within 4 hours (within 1 hour if the person has suspected sepsis and meets any of the high risk criteria for this – see the NICE guideline on sepsis). Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics. If intravenous antibiotics are given, review by 48 hours and consider ...